Literature DB >> 29579876

Orthotopic Liver Transplantation: Preliminary Analysis of Complications With Grafts From Elderly Donors.

J R Naranjo-Izurieta1, Z Ruiz de Azúa-López2, J Lameirao3, L Martín-Villén2, A Roldán-Reina3, M Porras-López3, A Rodríguez-Rodríguez3, J J Egea-Guerrero4.   

Abstract

OBJECTIVE: This study aims to determine if donor grafts of patients older than 65 years develop more post-transplantation complications than those of younger patients.
DESIGN: This is a retrospective, observational study of liver transplant recipients during 12 months in Virgen del Rocio University Hospital. We compare incidence rates of reperfusion syndrome, acute kidney injury, and need for intra- and postoperative red blood cell transfusions in two donor age groups in which group A is <65 years old and group B is ≥65 years old.
RESULTS: Sixty cases were included. Reperfusion syndrome, acute kidney injury, and both intra- and postoperative red blood cell transfusion were more frequent in group A than group B (11.4% vs. 4%, P = .390; 44% vs. 32%, P = .423; 68.8% vs. 48%, P = .120; and 70.6% vs. 64%, P = .779, respectively). Six recipients (17.1%) died at 12 months from group A whereas there were no deaths register in group B during that time (P = .036).
CONCLUSION: Our results showed that including elderly donors does not aggravate incidence of complications, emphasizing that advanced age should not be an exclusion criteria for liver transplantation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29579876     DOI: 10.1016/j.transproceed.2017.12.034

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Optimizing the Use of Geriatric Livers for Transplantation in the Eurotransplant Region.

Authors:  Jacob D de Boer; Joris J Blok; Hein Putter; Jacob J E Koopman; Bart van Hoek; Undine Samuel; Marieke van Rosmalen; Herold J Metselaar; Ian P J Alwayn; Markus Guba; Andries E Braat
Journal:  Liver Transpl       Date:  2019-02       Impact factor: 5.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.